未登录

T

Tim E. Moors

VU University Medical Center

H指数:12

被引数:2,387

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Quantitative biochemical profiling of GCase activity and α-synuclein proteoforms in post-mortem human brains from GBA-related and idiopathic Parkinson’s disease

定量生化分析GBA相关性和特发性帕金森病患者死后人脑中GCase活性和α-突触核蛋白蛋白型

npj Parkinsons Disease

IF8.2

2026-08-050

OA

C-terminus-dependent detection of lysosomal alpha-synuclein in nigral Parkinson’s disease human brain neurons

C-末端依赖性的帕金森病黑质人脑神经元溶酶体α-突触核蛋白检测

Molecular Neurodegeneration

IF17.5

2025-11-010

OAAI

Acute lipid droplet accumulation induced by the inhibition of the phospholipase DDHD2 does not affect the level, solubility, or phosphoserine-129 status of α-synuclein

METABOLIC BRAIN DISEASE

IF3.5

2025-01-240

PRE

Reducing the lipase LIPE in mutant α-synuclein mice improves Parkinson-like deficits and reveals sex differences in fatty acid metabolism

减少突变型 α-突触核蛋白小鼠中的脂肪酶LIPE可改善帕金森样缺陷并揭示脂肪酸代谢的性别差异

NEUROBIOLOGY OF DISEASE

IF5.6

2024-09-012

OAAI

Altered TFEB subcellular localization in nigral neurons of subjects with incidental, sporadic and GBA-related Lewy body diseases

ACTA NEUROPATHOLOGICA

IF9.3

2024-04-060

OAAI

Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson's disease phenotypes (vol 10, 47, 2024)

NPJ PARKINSONS DISEASE

IF8.2

2024-03-120

OAAI

Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson's disease phenotypes

NPJ PARKINSONS DISEASE

IF8.2

2024-02-294

OAAI

Defining a Lewy Body: Running Up the Hill of Shifting Definitions and Evolving Concepts

JOURNAL OF PARKINSONS DISEASE

IF5

2024-01-042

OAAI

Increased palmitoylation improves estrogen receptor alpha-dependent hippocampal synaptic deficits in a mouse model of synucleinopathy

SCIENCE ADVANCES

IF12.5

2023-11-175

OAAI

Dynamic physiological α-synuclein S129 phosphorylation is driven by neuronal activity

动态生理 α-突触核蛋白S129磷酸化由神经元活动驱动

NPJ PARKINSONS DISEASE

IF8.2

2023-01-1641

OAAI

Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies

ACTA NEUROPATHOLOGICA COMMUNICATIONS

IF5.7

2022-06-037

OAAI

Wild-type GBA1 increases the α-synuclein tetramer-monomer ratio, reduces lipid-rich aggregates, and attenuates motor and cognitive deficits in mice

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2021-07-2924

OAAI

The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy

ACTA NEUROPATHOLOGICA

IF9.3

2021-06-1162

OAAI

Alterations in Sub-Axonal Architecture Between Normal Aging and Parkinson's Diseased Human Brains Using Label-Free Cryogenic X-ray Nanotomography

FRONTIERS IN NEUROSCIENCE

IF3.2

2020-11-255

OAAI

Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels

NEUROBIOLOGY OF DISEASE

IF5.6

2019-01-0150

PREAI

Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies

Molecular Neurobiology

IF4.3

2018-06-080

OAAI

Origin of α-mannosidase activity in CSF

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

IF2.8

2017-06-018

PREAI

Therapeutic potential of autophagy-enhancing agents in Parkinson's disease

MOLECULAR NEURODEGENERATION

IF17.5

2017-01-25236

OAAI

Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links

MOVEMENT DISORDERS

IF7.6

2016-02-29135

PREAI

Lysosomal enzyme activities in human brain

JOURNAL OF BIOTECHNOLOGY

IF3.9

2014-09-010

PREAI